- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01133860
Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease
July 22, 2011 updated by: IRCCS Policlinico S. Matteo
An Exploratory Phase II Dose Escalation Study of Eltrombopag in MYH9 Related Disease
The term MYH9-related disease (MYH9RD) includes four genetic disorders: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome.
All these disorders derive from mutation of a unique gene, named MYH9, and they have been recognized as different clinical presentations of a single illness that was named MYH9RD.
All patients affected by MYH9RD present since birth with thrombocytopenia, which can result in a variable degree of bleeding diathesis; some of them subsequently develop additional clinical manifestations, such as renal damage, sensorineural hearing loss, and/or presenile cataracts.
Eltrombopag is an oral thrombopoietin receptor agonist that stimulates proliferation and differentiation of megakaryocytes, the bone marrow cells that produce blood platelets.
This drug is effective in increasing platelet count in healthy volunteers, as well as in patients affected by some acquired thrombocytopenias, such as idiopathic thrombocytopenic purpura and HCV related thrombocytopenia.
The purpose of this study is to determine if eltrombopag, administered orally at the dose of 50 or 75 mg/daily for up to 6 weeks, is effective in increasing platelet count of patients affected by MYH9RD.
Further aims of this study are to test if eltrombopag is effective in reducing bleeding tendency of MYH9RD patients; to evaluate safety and tolerability of eltrombopag in patients with MYH9RD; to evaluate in vitro function of platelets produced during therapy in patients responding to this drug.
Study Overview
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Padova, Italy, 35128
- Azienda Ospedaliero-Universitaria di Padova, Unità di Medicina Generale e Patologia Speciale
-
Pavia, Italy, 27100
- Fondazione IRCCS Policlinico San Matteo, Unità di Medicina III
-
Perugia, Italy, 06122
- Policlinico Monteluce, Sezione di Medicina Interna e Cardiovascolare
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 16 years or more
- Confirmed diagnosis of MYH9-related disease
- Average platelet count for the previous year less than 50x10e9/L
- Written informed consent
Exclusion Criteria:
- Diseases known to involve the risk of thromboembolic events (e.g. atrial fibrillation)
- History of thrombosis within 1 year
- Use of drugs that affect platelet function (including but not limited to, aspirin, clopidogrel or NSAIDS) or anti-coagulants
- Females who are pregnant or nursing (a negative pregnancy test in required before enrollment of fertile women)
- Formal refusal of any recommendation of a safe contraception
- Alcohol or drug addiction
- Altered renal function as defined by creatinine of 20 mg/L or more
- Any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioral problems. HCV positivity and liver diseases will not be considered an exclusion criterion since a phase II study showed that eltrombopag was effective and safe in this patient population.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: eltrombopag
|
Eltrombopag, administered orally, 50 mg/daily for 21 days.
Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days.
Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days.
Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response to Drug Based on Platelet Count at the End of Therapy
Time Frame: 21 days and/or 42 days of therapy, 15 and 30 days after the end of therapy
|
The primary endpoints were the achievement of a platelet count over 100 x10e9/L or at least 3 times the baseline value (major response), or at least twice the baseline value but less than major response (minor response).
The overall response to therapy is reported.
Platelet count was measured at the end of therapy (21 or 42 days, see study design) by phase-contrast microscopy.
|
21 days and/or 42 days of therapy, 15 and 30 days after the end of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bleeding Tendency Assessed by WHO Bleeding Score
Time Frame: 21 days and/or 42 days of therapy, 15 and 30 days after the end of therapy
|
The percentage of patients with bleeding diathesis (grade 1, i.e. cutaneous bleeding, or grade 2, i.e. mild blood loss, according to WHO bleeding score) was calculated at baseline and at the end of therapy.
The results are expressed as the mean change in the percentage of patients with bleeding diathesis (95%CI).
|
21 days and/or 42 days of therapy, 15 and 30 days after the end of therapy
|
All Types of Adverse Events
Time Frame: 21 days and/or 42 days of therapy, 15 and 30 days after the end of therapy
|
All type of adverse events were registered.Results indicate the number of participants who experience a side effect of the drug.
|
21 days and/or 42 days of therapy, 15 and 30 days after the end of therapy
|
in Vitro Function of Platelets Produced During Therapy in Responding Patients
Time Frame: 21 days or 42 days of therapy
|
in vitro platelet function will be assessed in patients achieving a platelet count of 100 x10e9/L or more at the end of the therapy
|
21 days or 42 days of therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Carlo Balduini, MD, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007 Nov 29;357(22):2237-47. doi: 10.1056/NEJMoa073275.
- Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, Ghiggeri GM, Ravazzolo R, Savino M, Del Vecchio M, d'Apolito M, Iolascon A, Zelante LL, Savoia A, Balduini CL, Noris P, Magrini U, Belletti S, Heath KE, Babcock M, Glucksman MJ, Aliprandis E, Bizzaro N, Desnick RJ, Martignetti JA. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet. 2000 Sep;26(1):103-5. doi: 10.1038/79063.
- Seri M, Savino M, Bordo D, Cusano R, Rocca B, Meloni I, Di Bari F, Koivisto PA, Bolognesi M, Ghiggeri GM, Landolfi R, Balduini CL, Zelante L, Ravazzolo R, Renieri A, Savoia A. Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet. 2002 Feb;110(2):182-6. doi: 10.1007/s00439-001-0659-1. Epub 2001 Dec 14.
- Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, Nigro A, Noris P, Gangarossa S, Rocca B, Gresele P, Bizzaro N, Malatesta P, Koivisto PA, Longo I, Musso R, Pecoraro C, Iolascon A, Magrini U, Rodriguez Soriano J, Renieri A, Ghiggeri GM, Ravazzolo R, Balduini CL, Savoia A. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore). 2003 May;82(3):203-15. doi: 10.1097/01.md.0000076006.64510.5c.
- McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH; TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36. doi: 10.1056/NEJMoa073255.
- Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T, Bozzi V, Mezzasoma AM, Melazzini F, Balduini CL. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood. 2010 Dec 23;116(26):5832-7. doi: 10.1182/blood-2010-08-304725. Epub 2010 Sep 15.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
May 28, 2010
First Submitted That Met QC Criteria
May 28, 2010
First Posted (Estimate)
May 31, 2010
Study Record Updates
Last Update Posted (Estimate)
July 26, 2011
Last Update Submitted That Met QC Criteria
July 22, 2011
Last Verified
July 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Eltrombopag-MYH9-2008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Platelet Disorders
-
The First Affiliated Hospital of Soochow UniversityRecruiting
-
University Hospital, GenevaCompletedAcquired Platelet DisorderSwitzerland
-
Ayman SaadSobi, Inc.Withdrawn
-
Institut National de la Santé Et de la Recherche...Enrolling by invitationCharacterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) (CATCH)Thrombocytopenia | Inherited Platelet DisorderFrance
-
M.D. Anderson Cancer CenterNot yet recruitingFamilial Platelet Disorder | HematopoieticUnited States
-
IRCCS Policlinico S. MatteoCompleted
-
Centre Hospitalier Universitaire, AmiensRecruitingPlatelet Aggregation | Heparin-induced Thrombocytopenia | Platelet Activation | Platelet DisorderFrance
-
Region StockholmKarolinska InstitutetRecruitingPlatelet Disorder | Thrombocytopathy | Platelet Function DisorderSweden
-
Aggredyne, Inc.CompletedPlatelet Dysfunction Due to Aspirin IngestionUnited States
-
Etablissement Français du SangUniversity of MarseilleCompleted
Clinical Trials on eltrombopag
-
Novartis PharmaceuticalsCompletedPurpura, Thrombocytopenic, IdiopathicRussian Federation
-
Fondazione Progetto EmatologiaCompletedChronic Lymphocytic Leukemia | Purpura, Thrombocytopenic, Idiopathic | Non Hodgkin's Lymphoma | Autoimmune Thrombocytopenia | Autoimmune Thrombocytopenic PurpuraItaly
-
Weill Medical College of Cornell UniversityNovartisTerminatedImmune ThrombocytopeniaUnited States
-
Institute of Hematology & Blood Diseases Hospital...Xijing Hospital; Xi'an Central Hospital; The Second Hospital of Hebei Medical... and other collaboratorsActive, not recruitingPreviously Treated Primary Immune ThrombocytopeniaChina
-
Tel-Aviv Sourasky Medical CenterNovartisRecruitingB Cell Lymphoma | CART TreatmentIsrael
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedPrimacy Immune ThrombocytopeniaItaly
-
Novartis PharmaceuticalsCompletedPurpura, Thrombocytopaenic, Idiopathic
-
Nanfang Hospital of Southern Medical UniversityGuangzhou First People's Hospital; Second Affiliated Hospital, Sun Yat-Sen... and other collaboratorsUnknownAcute Myeloid Leukemia | Thrombocytopenia | EltrombopagChina
-
IRCCS Policlinico S. MatteoCompleted